MIH
ALNY icon

Meitav Investment House’s Alnylam Pharmaceuticals ALNY Stock Holding History

Meitav Investment House’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-111,610
Closed -$8.14M – 391
2018
Q4 		$8.14M Sell
111,610
-90
-0.1% -$6.92K 0.5% 57
2018
Q3 		$10.1M Buy
111,700
+56,700
+103% +$5.7M 0.49% 53
2018
Q2 		$5.41M Buy
+55,000
New +$5.46M 0.24% 77

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meitav Investment House's ALNY Position: Q1 2019 in Review

Meitav Investment House sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2019, closing a stake of 111,610 shares — an estimated $8.14M sold.

Meitav Investment House first reported a position in ALNY in Q2 2018 and held it in 3 quarters. The position peaked at $10.1M in Q3 2018. 291 funds tracked by Wall St. Rank hold ALNY as of Q1 2019.

  • Meitav Investment House reported no remaining Alnylam Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Meitav Investment House sold 111,610 Alnylam Pharmaceuticals shares in Q1 2019, an estimated $8.14M.
  • Meitav Investment House first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Meitav Investment House's Alnylam Pharmaceuticals position peaked at $10.1M in Q3 2018.
  • 291 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2019.

Based on Meitav Investment House's 13F filing for Q1 2019, filed 13 May 2019.